Area of research
Oncology · Radiology, Nuclear Medicine and Imaging
Research interest
Research interests include Cancer Immunotherapy and Biomarkers, HER2/EGFR in Cancer Research, Monoclonal and Polyclonal Antibodies Research, and Cancer Genomics and Diagnostics.
Milademetan in Advanced Solid Tumors with <i>MDM2</i> Amplification and Wild-type <i>TP53</i>: Preclinical and Phase II Clinical Trial Results
PSCA-targeted BPX-601 CAR T cells with pharmacological activation by rimiducid in metastatic pancreatic and prostate cancer: a phase 1 dose escalation trial
654 XMT-2056: a phase 1 study of a HER2-directed STING agonist antibody drug conjugate (ADC) in HER2+ solid tumors
A phase 1/2 study of BDC-3042, a novel dectin-2 agonistic antibody, in patients with advanced cancers.
First-in-human study of PC14586, a small molecule structural corrector of Y220C mutant p53, in patients with advanced solid tumors harboring a <i>TP53</i> Y220C mutation.
A phase 2 study of the MDM2 inhibitor milademetan in patients with <i>TP53</i>-wild type and <i>MDM2</i>-amplified advanced or metastatic solid tumors (MANTRA-2).
A phase 1b study of nivolumab in patients with autoimmune disorders and advanced malignancies (AIM-NIVO).
Phase 2 study of pembrolizumab in patients with advanced rare cancers